» Articles » PMID: 11734427

Longitudinal Changes in Physiological, Radiological, and Health Status Measurements in Alpha(1)-antitrypsin Deficiency and Factors Associated with Decline

Overview
Specialty Critical Care
Date 2001 Dec 6
PMID 11734427
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

The FEV(1) declines rapidly in alpha(1)-antitrypsin deficiency (alpha(1)-ATD) but less is known about other measures of disease severity and the factors, other than smoking, that are associated with progression of emphysema. The natural history of alpha(1)-ATD was studied prospectively in 43 patients with the PiZ phenotype and emphysema at a single center over 2 yr. The mean +/- SE change in FEV(1) was -67 +/- 14 ml/yr, accompanied by a reduction in transfer factor (mean change in diffusing capacity of the lung for CO [DL(CO)] -1.07 +/- 0.21 ml/min/mm Hg/yr; p < 0.001) and lung density in the upper zones as assessed by quantitative high-resolution computed tomography (HRCT) (mean change in voxel index 2.8 +/- 0.6%/yr; p < 0.001). The decline in FEV(1) related to baseline FEV(1) (r = -0.56, p < 0.001), bronchodilator reversibility (r = 0.52, p < 0.001), and (for patients with FEV(1) > 35% predicted) exacerbation frequency (r = -0.38, p = 0.02). There was also a decline in the St. George's Respiratory Questionnaire (SGRQ) Activity score (mean change -4.3 +/- 1.2 units/yr, p < 0.001) that correlated with FEV(1) decline (r = 0.45, p = 0.002). Progression of emphysema in alpha(1)-ATD is dependent on baseline physiology and exacerbation frequency and may be detected by several different measurements of which HRCT density mask analysis and DL(CO) appear most sensitive.

Citing Articles

Advancing the understanding and treatment of lung pathologies associated with alpha 1 antitrypsin deficiency.

Turner A, Ficker J, Vianello A, Clarenbach C, Janciauskiene S, Chorostowska-Wynimko J Ther Adv Respir Dis. 2025; 19:17534666251318841.

PMID: 39980299 PMC: 11843710. DOI: 10.1177/17534666251318841.


Long-Term SGRQ Stability in a Cohort of Individuals with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease.

Choate R, Holm K, Sandhaus R, Mannino D, Strange C Int J Chron Obstruct Pulmon Dis. 2024; 19:889-900.

PMID: 38617018 PMC: 11016265. DOI: 10.2147/COPD.S443183.


Nine controversial questions about augmentation therapy for alpha-1 antitrypsin deficiency: a viewpoint.

Miravitlles M, Anzueto A, Barrecheguren M Eur Respir Rev. 2023; 32(170).

PMID: 38056890 PMC: 10698548. DOI: 10.1183/16000617.0170-2023.


The effect of exacerbations on lung density in α-antitrypsin deficiency.

Strange C, McElvaney N, Vogelmeier C, Marin-Galiano M, Buch-Haensel M, Zhang X ERJ Open Res. 2023; 9(2).

PMID: 36923570 PMC: 10009703. DOI: 10.1183/23120541.00457-2022.


Clinical Trial of Losartan for Pulmonary Emphysema: Pulmonary Trials Cooperative Losartan Effects on Emphysema Progression Clinical Trial.

Wise R, Holbrook J, Brown R, Criner G, Dransfield M, He J Am J Respir Crit Care Med. 2022; 206(7):838-845.

PMID: 35649189 PMC: 9799269. DOI: 10.1164/rccm.202201-0206OC.